Evommune, Inc. (EVMN) - Total Assets
Based on the latest financial reports, Evommune, Inc. (EVMN) holds total assets worth $224.95 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Evommune, Inc. - Total Assets Trend (2023–2025)
This chart illustrates how Evommune, Inc.'s total assets have evolved over time, based on quarterly financial data. Also see EVMN stock market capitalisation for the company's overall valuation and market capitalisation.
Evommune, Inc. - Asset Composition Analysis
Current Asset Composition (December 2025)
Evommune, Inc.'s total assets of $224.95 Million consist of 68.2% current assets and 31.8% non-current assets. Review EVMN current and long-term liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 19.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2023–2025)
This chart illustrates how Evommune, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest Evommune, Inc. stock price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Evommune, Inc.'s current assets represent 68.2% of total assets in 2025, a decrease from 97.3% in 2023.
- Cash Position: Cash and equivalents constituted 19.6% of total assets in 2025, down from 35.3% in 2023.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2023.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Evommune, Inc. Competitors by Total Assets
Key competitors of Evommune, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
F:A71
|
Germany | €2.00 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX
|
USA | $547.14 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Kailera Therapeutics, Inc. Common Stock
NASDAQ:KLRA
|
USA | $1.21 Billion |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
|
USA | $512.24 Million |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068
|
China | CN¥3.21 Billion |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Evommune, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.57 | 2.64 | 2.64 |
| Quick Ratio | 8.57 | 2.64 | 2.64 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $135.57 Million | $46.01 Million | $46.01 Million |
Evommune, Inc. - Advanced Valuation Insights
This section examines the relationship between Evommune, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.16 |
| Latest Market Cap to Assets Ratio | 1.36 |
| Asset Growth Rate (YoY) | 195.8% |
| Total Assets | $224.95 Million |
| Market Capitalization | $305.80 Million USD |
Valuation Analysis
Above Book Valuation: The market values Evommune, Inc.'s assets above their book value (1.36x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Evommune, Inc.'s assets grew by 195.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Evommune, Inc. (2023–2025)
The table below shows the annual total assets of Evommune, Inc. from 2023 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $224.95 Million | +195.77% |
| 2024-12-31 | $76.06 Million | -7.53% |
| 2023-12-31 | $82.25 Million | -- |
About Evommune, Inc.
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of … Read more